Go to main content
R&D JW, leading global new drug development
Home

Pipeline

Our Pipeline at a Glance

31

Compounds in
Development

Disease Area

Oncology Immunological Diseases Cardiovascular and Metabolic Diseases Regenerative Medicine Rare Diseases Ophthalmic Diseases Digestive System Nutrition Urology Others
In the Pipeline
Pre-Clinical Phase 1 Phase 2 Phase 3 Approval

Oncology

 WE
X
WE – Pre-Clinical
Mechanism of Action:
Wee/Myt1 dual inhibitor
Indications:
Partner:
Additional Information:
Best-in-class
Substance Type:
 		JW2286
X
JW2286 – Phase 1
Mechanism of Action:
STAT3 inhibitor
Indications:
Partner:
Additional Information:
First-in-class
Substance Type:
 		MOBILIA
(2024)
X
MOBILIA (2024) – Approval
Mechanism of Action:
CXCR4 antagonist
Indications:
Mobilization of hematopoietic stem cells into the peripheral blood for autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma and multiple myeloma
Storage:
Store at room temperature (15–30°C) in a tightly closed container
Strength:
Plerixafor 20mg/mL
Additional Information:
Hematopoietic stem cell mobilizer
Administration:
Subcutaneous injection (administer approximately 11 hours before the start of hematopoietic stem cell collection)
Active Ingredient:
Plerixafor
Description:
Clear, colorless to pale yellow solution in a clear, colorless vial
DK

Immunological Diseases

 SI
X
SI – Pre-Clinical
Mechanism of Action:
Indications:
Partner:
Additional Information:
Best-in-class
Substance Type:
 		TAVALISSE
(2025)
X
TAVALISSE(2025) – Approval
Mechanism of Action:
Spleen Tyrosine Kinase inhibitor
Indications:
Thrombocytopenia
Storage:
Store at room temperature (1–30°C) in a tightly closed container
Strength:
Fostamatinib Disodium Hexahydrate 189.3mg
Additional Information:
First-in-class
Administration:
100mg orally twice daily (with or without food)
Active Ingredient:
Fostamatinib Disodium Hexahydrate
Description:
Light reddish-yellow, oval, film-coated tablet

Cardiovascular and
Metabolic Diseases

 TP
X
TP – Pre-Clinical
Mechanism of Action:
Indications:
Partner:
Additional Information:
First-in-class
Substance Type:
 		JW0110
X
JW0110 – Phase 1
Mechanism of Action:
Indications:
Diabetes + hyperlipidemia
Partner:
Additional Information:
Modified new drug (fixed-dose combination)
Substance Type:
 		LIVALOZET HI
X
LIVALOZET HI – Phase 3
Mechanism of Action:
HMG-CoA reductase, Niemann-Pick C1 Like 1 Protein Blocker, Calcium channel blocker, Angiotensin-receptor blocker
Indications:
Hyperlipidemia, hypertension
Storage:
Strength:
2/10/80/5mg, 4/10/80/5mg, 2/10/160/5mg, 4/10/160/5mg, 4/10/160/10mg
Additional Information:
Fixed-dose combination
Administration:
Orally once daily
Active Ingredient:
Pitavastatin, Ezetimibe, Amlodipine, Valsartan
Description:
 		LIVALO HI
(2025)
X
LIVALO HI(2025) – Approval
Mechanism of Action:
HMG-CoA reductase, Calcium channel blocker, Angiotensin-receptor blocker
Indications:
Hyperlipidemia, hypertension
Storage:
Store at room temperature (1–30°C) in a tightly closed container
Strength:
2/80/5, 4/80/5, 2/160/5, 2/160/10, 4/160/5, 4/160/10mg
Additional Information:
Triple combination
Administration:
Orally once daily
Active Ingredient:
Pitavastatin Ca / Valsartan / Amlodipine besylate
Description:
2/80/5, 4/80/5 mg: Round, film-coated tablet
2/160/5, 2/160/10, 4/160/5, 4/160/10mg: Oblong, film-coated tablet
TS
X
TS – Pre-Clinical
Mechanism of Action:
Indications:
Partner:
Additional Information:
Best-in-class
Substance Type:
 		EMPA-GUARD
X
EMPA-GUARD – Phase 3
Mechanism of Action:
DPP4 inhibitor, SGLT2 inhibitor
Indications:
Type 2 diabetes mellitus
Partner:
SKK
Additional Information:
Modified new drug, currently under NDA review
Substance Type:
Fixed-dose combination
 		LIVALO Z
(2021)
X
LIVALO Z(2021) – Approval
Mechanism of Action:
HMG-CoA reductase,
Niemann-Pick C1 Like 1 Protein Blocker
Indications:
Hyperlipidemia
Storage:
Store at room temperature (1–30°C)
Strength:
2/10, 4/10 mg
Additional Information:
Modified new drug (fixed-dose combination)
Administration:
Orally once daily
Active Ingredient:
Pitavastatin Ca/Ezetimibe
Description:
Round, film-coated tablet
EPAMINURAD
X
EPAMINURAD – Phase 3
Mechanism of Action:
Urate anion exchanger 1 inhibitor
Indications:
Gout
Partner:
Simcere Pharmaceutical
Additional Information:
Best-in-Class
Substance Type:
Synthetic new drug
 		LIVALO V
(2015)
X
LIVALO V(2015) – Approval
Mechanism of Action:
HMG-CoA reductase, Angiotensin-receptor blocker
Indications:
Hyperlipidemia, hypertension
Storage:
Store at room temperature (1–30°C)
Strength:
2/80, 4/80, 2/160, 4/160 mg
Additional Information:
Fixed-dose combination
Administration:
Orally once daily
Active Ingredient:
Pitavastatin Ca/Valsartan
Description:
2/80, 4/80 mg: Round, film-coated tablet
2/160, 4/160 mg: Oblong, film-coated tablet
JDART
(2018)
X
JDART(2018) – Approval
Mechanism of Action:
5 α-reductase inhibitors
Indications:
Improvement and control of progression of symptoms of benign prostatic hyperplasia
Storage:
Store in a tightly closed container at room temperature (1–30°C)
Strength:
0.5mg
Additional Information:
Treatment of benign prostatic hyperplasia and male pattern hair loss
Administration:
One tablet orally once daily (swallow whole without chewing or splitting)
Active Ingredient:
Dutasteride
Description:
Light yellow, oval film-coated tablet

Regenerative Medicine

 JW0061
X
JW0061 – Phase 1
Mechanism of Action:
GFRA1 agonist
Indications:
Alopecia
Partner:
Additional Information:
First-in-class
Substance Type:
Synthetic new drug

Rare Diseases

 ND
X
ND – Pre-Clinical
Mechanism of Action:
Indications:
Partner:
Additional Information:
First-in-class
Substance Type:
 		HEMLIBRA
(2024)
X
HEMLIBRA(2024) – Approval
Mechanism of Action:
Bispecific monoclonal antibody that binds coagulation factors IX and X and mimics the function of activated factor VIII
Indications:
Routine prophylaxis to reduce or prevent bleeding episodes in patients with hemophilia A (factor VIII deficiency), with or without factor VIII inhibitors
Storage:
Store in a tightly closed container at 2–8°C, protected from light
Strength:
30mg/mL, 60mg/0.4mL, 105mg/0.7mL, 150mg/mL
Additional Information:
Non-factor therapy
Administration:
Subcutaneous injection (maintenance dosing once weekly, once every 2 weeks, or once every 4 weeks)
Active Ingredient:
Emicizumab
Description:
Colorless to pale yellow solution in a clear, colorless vial

Ophthalmic Diseases

 JW1601
X
JW1601 – Pre-Clinical
Mechanism of Action:
Indications:
Ophthalmic diseases
Partner:
Additional Information:
First-in-class
Substance Type:

Digestive System

 RABEKHAN DUO
(2024)
X
RABEKHAN DUO(2024) – Approval
Mechanism of Action:
Indications:
Gastric ulcer, duodenal ulcer, gastroesophageal reflux disease (GERD), and maintenance therapy
Storage:
Store in a tightly closed container at room temperature (1–30°C)
Strength:
10/700, 20/700 mg
Additional Information:
Fixed-dose combination
Administration:
Orally once daily
Active Ingredient:
Rabeprazole Sodium / Sodium Bicarbonate
Description:
Oval, film-coated tablet (color varies by strength, such as light yellow and light pink)

Nutrition

 JNT WINUF
(2013)
X
WINUF(2013) – Approval
Mechanism of Action:
Provides four lipid components including high-content purified fish oil, together with glucose, amino acids, and electrolytes to maintain nutritional balance and provide anti-inflammatory effects
Indications:
Parenteral nutrition for patients in whom oral or enteral nutrition is impossible, insufficient, or contraindicated (supplies amino acids, carbohydrates, lipids, and electrolytes)
Storage:
Store in a tightly closed container at room temperature (1–25°C)
Strength:
Varies by product line (362mL, 725mL, 1085mL, 1450mL, 2170mL, etc.)
Additional Information:
3-chamber bag parenteral nutrition (omega-3-containing TPN)
Administration:
Intravenous injection
Active Ingredient:
Purified fish oil, purified soybean oil, medium-chain triglycerides (MCT), purified olive oil, amino acids, glucose, electrolytes, etc.
Description:
Injection in a transparent plastic bag divided into three chambers, containing a clear, colorless to pale yellow solution (glucose, amino acids) and a white emulsion (lipids)
WINUF A+
(2023)
X
WINUF A+(2023) – Approval
Mechanism of Action:
Promotes muscle synthesis and improves nutritional status by supplying high-content amino acids and taurine, four types of lipids (including omega-3), glucose, and electrolytes
Indications:
Parenteral nutrition for patients in whom oral or enteral nutrition is impossible, insufficient, or contraindicated, especially critically ill or postoperative patients who require high protein intake
Storage:
Store in a tightly closed container at room temperature (1–30°C)
Strength:
Varies by product line (central venous: 1,000/1,500/2,000mL; peripheral venous: 725/1,085/1,450mL, etc.)
Additional Information:
High-amino-acid 3-chamber bag parenteral nutrition (with taurine)
Administration:
Intravenous injection (Winuf A Plus: central venous administration / Winuf A Plus Peri: peripheral venous administration)
Active Ingredient:
Purified fish oil, purified soybean oil, medium-chain triglycerides (MCT), purified olive oil, amino acids, glucose, electrolytes, taurine
Description:
Injection in a transparent plastic bag divided into three chambers, containing a clear, colorless to pale yellow solution (glucose, amino acids) and a white lipid emulsion

Urology

 THRUPASS Comb. THRUPASS
(2009)
JDART
(2018)

Others

 LINZAGOLIX
X
LINZAGOLIX – Phase 3
Mechanism of Action:
GnRH antagonist
Indications:
Bleeding caused by uterine fibroids
Partner:
Kissei
Additional Information:
Substance Type:
Synthetic new drug
 		ENAROY
(2022)
X
ENAROY(2022) – Approval
Mechanism of Action:
Hypoxia Inducible Factor-Prolyl Hydroxylase inhibitor
Indications:
Treatment of anemia in patients with chronic kidney disease (renal anemia)
Storage:
Store in a tightly closed container at room temperature (1–30°C)
Strength:
1, 2, 4 mg
Additional Information:
Oral treatment for renal anemia (new drug)
Administration:
Orally once daily
Active Ingredient:
Enarodustat
Description:
Round, film-coated tablet (color varies by strength, including light yellow, light orange, and light red)
TENOFECTION
(2022)
X
TENOFECTION(2022) – Approval
Mechanism of Action:
HBV DNA polymerase inhibitor
Indications:
Treatment of chronic hepatitis B
Storage:
Store in a tightly closed container at room temperature (1–30°C)
Strength:
300mg
Additional Information:
Administration:
Orally once daily
Active Ingredient:
Tenofovir Disoproxil Phosphate
Description:
Light blue, almond-shaped film-coated tablet
X
Oncology
JW’s vision in oncology is to change the paradigm of cancer treatment and improve the quality of life of patients with cancer.

To achieve this, we are focused on the research and development of targeted anticancer therapies and immune cell therapies.

Beginning with the development of the first dendritic cell-based immune cell therapy for metastatic renal cell carcinoma, JW has deepened its understanding of immuno-oncology through differentiated clinical development programs across various cancer types.

We are also continuing research to identify biomarkers that can help predict which patients are most likely to benefit from targeted anticancer therapies and immune cell therapies.

In addition to its immuno-oncology portfolio, JW is investigating signaling mechanisms involved in tumor development and is developing oncology programs that target Wnt and STAT signaling pathways.
X
Cardiovascular and Metabolic Diseases
Cardiovascular diseases include all conditions related to the heart and blood vessels.

JW is seeking treatments that can improve cardiovascular care, with a focus on hyperlipidemia and hypertension, for patients whose lives are threatened by cardiovascular and metabolic diseases.

We are also committed to improving quality of life and addressing unmet medical needs.

In clinical studies involving Korean patients with acute myocardial infarction, Livalo (pitavastatin) demonstrated not only a reduction in major cardiac events but also improvement in blood glucose control, supporting its profile as a treatment with no increased risk of diabetes.

JW is also developing various combination products using its own technology to improve dosing convenience for patients with both hyperlipidemia and hypertension by enabling multiple required ingredients to be taken together.

In addition, JW is working to discover new treatments for metabolic diseases that are not adequately managed by existing therapies, based on molecular-level mechanism research.
X
Immunological Diseases
By continuously expanding its expertise in immunology, JW is striving to develop innovative medicines for patients with diseases such as atopic dermatitis, gout, asthma, and idiopathic pulmonary fibrosis.

JW’s goal is to develop treatments that address the root causes of chronic inflammatory diseases at the molecular level, beyond conventional therapies that mainly relieve symptoms.
X
Regenerative Medicine
Regenerative medicine is a field of medicine that replaces or regenerates human cells, tissues, and organs to restore their original functions.

JW’s goal is to regenerate damaged areas by activating the body’s own recovery mechanisms in tissues and organs that were previously considered irrecoverable.

In particular, JW focuses on Wnt signaling and other pathways involved in stem cell growth, differentiation, and related signaling, and is working to develop fundamental molecular-level treatments in regenerative medicine for hair follicle regeneration as well as muscle and brain disorders.
X
Rare Diseases
Under the Rare Disease Management Act, a rare disease is defined as a disease affecting fewer than 20,000 patients, or a disease for which the number of affected patients is unknown due to difficulties in diagnosis.

JW is working to develop effective treatments for patients with rare diseases, including hemophilia.
X
Ophthalmic Diseases
Vision loss is a major health and social issue affecting more than one billion people worldwide. It can limit social interaction and independence, reduce a patient’s ability to work, and lead to depression and anxiety.

JW is working to discover new treatments based on molecular-level mechanism research for diseases such as diabetic retinopathy (DR) and age-related macular degeneration (AMD), where current treatment options remain limited.
X
Diagnostics
JWBS-R001, Phase 1
Novel biomarker for sepsis diagnosis
  • WRS, Tryptophanyl tRNA synthetase (53KDa)
  • Rapidly secreted into the blood during infection and involved in innate immune responses
  • WRS is a reliable, specific, and sensitive biomarker for sepsis
    (Ahn YH et al., Nature Microbiology, 2016)
POCT
  • Rapid diagnostic platform with central lab-level performance
  • Automated analyzer using chemiluminescence technology
  • Analysis time within 20 minutes, with up to 6 cartridges analyzed simultaneously
Patent
  • Composition for diagnosing infectious disease or infectious complications using tryptophanyl-tRNA synthetase and method for detecting diagnostic markers (2016. 03. 02)
  • Antibody specifically binding to WRS protein and uses thereof (2019. 07. 18)
JWBS-R002, Preclinical
Novel biomarker for pancreatic cancer diagnosis
  • CFB, Complement factor B (93KDa)
  • Diagnostic accuracy for pancreatic cancer is improved when CFB and CA19-9 are used together
  • The world’s first pancreatic cancer diagnostic kit using multiple biomarkers
Patent
  • Pancreatic cancer diagnostic kit comprising an antibody specifically binding to complement factor B protein (2014. 05. 12)
X
IV Fluids
WINUF
  • Indication: Parenteral nutrition
  • Ingredients: Dextrin / Amino acids / Lipid emulsion, 3-chamber system
  • Volume: 1085mL, 1435mL, 1820mL, 1450mL, 2020mL
  • Packaging Material: Non-PVC plastic bag
Everamin Injection
  • Indication: Parenteral nutrition
  • Ingredients: Amino acids (glycine, arginine, isoleucine, etc.)
  • Volume: 100/250mL
  • Packaging Material: Non-PVC plastic bag
Acetapen Injection
  • Indication: Pain and fever
  • Ingredient: Acetaminophen 10mg
  • Volume: 100mL
  • Packaging Material: Non-PVC plastic bag
Levetiram Injection
  • Indication: Anticonvulsant
  • Ingredient: Levetiracetam 1000mg
  • Volume: 110mL
  • Packaging Material: Non-PVC plastic bag